TapewireFind a company

person · Reporting owner

Rodino-Klapac Louise

Disclosed activity across 1 company

Tapewire entity
61123
SEC CIK
0001836218

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Sarepta Therapeutics, Inc.SRPT · Entity 4426President, R&D and Tech OpsSeptember 04, 2026September 09, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Sarepta Therapeutics, Inc.

Report date September 04, 2026 · Filed September 09, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect203,900 Reported balance After 2026-09-04 transaction · row 1
1 source row

Row 1 · 2026-09-04 · Tax withholding · Disposed 21,423 · Balance 203,900

F1: Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on September 3, 2025.

Filing footnotes · ownership attribution and instrument terms

F1: Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on September 3, 2025.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
September 04, 2026 Filed Sep 9, 2026 00:01 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 Tax withholdingCommon Stock 21,423 $22.22 $476,019.06
Disclosure

SEC source: 0001193125-26-385536 · ownership.xml · nonDerivative · entry 1

Rodino-Klapac Louise · CIK 0001836218 · President, R&D and Tech Ops

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 203,900

F1 · kind: Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on September 3, 2025.

Read SEC document
March 11, 2026 Filed Mar 14, 2026 00:05 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 Tax withholdingCommon Stock 948 $17.03 $16,144.44
Disclosure

SEC source: 0001193125-26-106703 · ownership.xml · nonDerivative · entry 1

Rodino-Klapac Louise · CIK 0001836218 · President, R&D and Tech Ops

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 225,323

F1 · kind: Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 10, 2025.

Read SEC document
March 09, 2026 Filed Mar 12, 2026 00:04 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 Tax withholdingCommon Stock 895 $16.95 $15,170.25
Disclosure

SEC source: 0001193125-26-102703 · ownership.xml · nonDerivative · entry 2

Rodino-Klapac Louise · CIK 0001836218 · President, R&D and Tech Ops

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 226,271

F2 · kind: Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 7, 2022.

Read SEC document
March 09, 2026 Filed Mar 12, 2026 00:04 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 Tax withholdingCommon Stock 504 $16.95 $8,542.80
Disclosure

SEC source: 0001193125-26-102703 · ownership.xml · nonDerivative · entry 1

Rodino-Klapac Louise · CIK 0001836218 · President, R&D and Tech Ops

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 227,166

F1 · kind: Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 6, 2023.

Read SEC document
March 02, 2026 Filed Mar 4, 2026 01:02 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 Tax withholdingCommon Stock 767 $16.20 $12,425.40
Disclosure

SEC source: 0001193125-26-089425 · ownership.xml · nonDerivative · entry 3

Rodino-Klapac Louise · CIK 0001836218 · President, R&D and Tech Ops

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 227,670

F3 · kind: Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 1, 2024.

Read SEC document
March 02, 2026 Filed Mar 4, 2026 01:02 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 Tax withholdingCommon Stock 3,718 $16.20 $60,231.60
Disclosure

SEC source: 0001193125-26-089425 · ownership.xml · nonDerivative · entry 2

Rodino-Klapac Louise · CIK 0001836218 · President, R&D and Tech Ops

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 228,437

F2 · kind: Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of a PSU award granted on March 1, 2024.

Read SEC document
March 01, 2026 Filed Mar 4, 2026 01:02 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 Exercise / conversionPerformance Stock Units · Derivative 8,125 $0.00 $0.00
Disclosure

SEC source: 0001193125-26-089425 · ownership.xml · derivative · entry 4

Rodino-Klapac Louise · CIK 0001836218 · President, R&D and Tech Ops

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 8,125 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Represents the number of shares previously earned under a PSU award granted to the Reporting Person on March 1, 2024. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of the prescribed milestones under the terms of the PSU award. The shares vested on March 1, 2026.

F1 · derivative.exercise_date: Represents the number of shares previously earned under a PSU award granted to the Reporting Person on March 1, 2024. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of the prescribed milestones under the terms of the PSU award. The shares vested on March 1, 2026.

F1 · derivative.expiration_date: Represents the number of shares previously earned under a PSU award granted to the Reporting Person on March 1, 2024. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of the prescribed milestones under the terms of the PSU award. The shares vested on March 1, 2026.

Read SEC document
March 01, 2026 Filed Mar 4, 2026 01:02 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 Exercise / conversionCommon Stock 8,125 Not disclosed Not disclosed
Disclosure

SEC source: 0001193125-26-089425 · ownership.xml · nonDerivative · entry 1

Rodino-Klapac Louise · CIK 0001836218 · President, R&D and Tech Ops

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 232,155

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Represents the number of shares previously earned under a PSU award granted to the Reporting Person on March 1, 2024. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of the prescribed milestones under the terms of the PSU award. The shares vested on March 1, 2026.

Read SEC document
February 25, 2026 Filed Feb 28, 2026 01:03 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 GrantPerformance Stock Units · Derivative 1,875 Not disclosed Not disclosed
Disclosure

SEC source: 0001193125-26-083671 · ownership.xml · derivative · entry 1

Rodino-Klapac Louise · CIK 0001836218 · President, R&D and Tech Ops

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,125

Underlying: Common Stock · 1,875 shares

Expires not disclosed

F1 · derivative.exercise_price: Represents the number of shares earned under a PSU award granted to the Reporting Person on March 1, 2024. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of the prescribed milestones under the terms of the PSU award. The earned PSUs will vest on March 1, 2026, subject to the Reporting Person continuing to provide service to the Company through such vesting date.

F1 · price: Represents the number of shares earned under a PSU award granted to the Reporting Person on March 1, 2024. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of the prescribed milestones under the terms of the PSU award. The earned PSUs will vest on March 1, 2026, subject to the Reporting Person continuing to provide service to the Company through such vesting date.

F1 · derivative.exercise_date: Represents the number of shares earned under a PSU award granted to the Reporting Person on March 1, 2024. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of the prescribed milestones under the terms of the PSU award. The earned PSUs will vest on March 1, 2026, subject to the Reporting Person continuing to provide service to the Company through such vesting date.

F1 · derivative.expiration_date: Represents the number of shares earned under a PSU award granted to the Reporting Person on March 1, 2024. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of the prescribed milestones under the terms of the PSU award. The earned PSUs will vest on March 1, 2026, subject to the Reporting Person continuing to provide service to the Company through such vesting date.

Read SEC document
November 17, 2025 Filed Nov 20, 2025 01:05 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 Tax withholdingCommon Stock 4,582 $18.42 $84,400.44
Disclosure

SEC source: 0001193125-25-288556 · ownership.xml · nonDerivative · entry 1

Rodino-Klapac Louise · CIK 0001836218 · President, R&D and Tech Ops

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 224,030

F1 · shares: Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on November 16, 2021.

Read SEC document
September 03, 2025 Filed Sep 6, 2025 01:30 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 GrantCommon Stock 50,000 $0.00 $0.00
Disclosure

SEC source: 0001193125-25-197425 · ownership.xml · nonDerivative · entry 2

Rodino-Klapac Louise · CIK 0001836218 · President, R&D and Tech Ops

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 228,612

F3 · shares: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. 100% of the RSUs will vest on September 3, 2028, subject to the Reporting Person's continued service to the Company and only if certain performance criteria has been deemed achieved by the Compensation Committee of the Board.

Read SEC document
September 03, 2025 Filed Sep 6, 2025 01:30 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 GrantCommon Stock 93,875 $0.00 $0.00
Disclosure

SEC source: 0001193125-25-197425 · ownership.xml · nonDerivative · entry 1

Rodino-Klapac Louise · CIK 0001836218 · President, R&D and Tech Ops

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 178,612

F1 · shares: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. 50% of the RSUs will vest on September 3, 2026, and the remaining 50% will vest on September 3, 2027, subject to the Reporting Person's continued service to the Company.

F2 · balance_after: Includes 106 shares of common stock purchased on August 31, 2025 through the Company's Employee Stock Purchase Plan

Read SEC document
August 05, 2025 Filed Aug 7, 2025 00:01 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 GrantPerformance Stock Units · Derivative 6,250 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-104397 · ownership.xml · derivative · entry 1

Rodino-Klapac Louise · CIK 0001836218 · President, R&D and Tech Ops

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,250

Underlying: Common Stock · 6,250 shares

Expires not disclosed

F1 · derivative.exercise_price: Represents the number of shares earned under a PSU award granted to the Reporting Person on March 1, 2024. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of the prescribed milestones under the terms of the PSU award. The earned PSUs will vest on March 1, 2026, subject to the Reporting Person continuing to provide service to the Company through such vesting date.

F1 · derivative.exercise_date: Represents the number of shares earned under a PSU award granted to the Reporting Person on March 1, 2024. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of the prescribed milestones under the terms of the PSU award. The earned PSUs will vest on March 1, 2026, subject to the Reporting Person continuing to provide service to the Company through such vesting date.

F1 · derivative.expiration_date: Represents the number of shares earned under a PSU award granted to the Reporting Person on March 1, 2024. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of the prescribed milestones under the terms of the PSU award. The earned PSUs will vest on March 1, 2026, subject to the Reporting Person continuing to provide service to the Company through such vesting date.

Read SEC document
March 10, 2025 Filed Mar 12, 2025 00:00 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 GrantStock Options (right to buy) · Derivative 16,644 $0.00 Strike: $99.69 $0.00
Disclosure

SEC source: 0000950170-25-037523 · ownership.xml · derivative · entry 6

Rodino-Klapac Louise · CIK 0001836218 · Head of R&D, CSO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,644

Underlying: Common Stock · 16,644 shares

Expires 2035-03-10

F5 · derivative.exercise_date: Represents the date upon which the first 25% of the option granted vests. 1/48th of the total granted option vests and become exercisable on each monthly anniversary thereafter.

Read SEC document
March 10, 2025 Filed Mar 12, 2025 00:00 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 GrantCommon Stock 8,276 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-25-037523 · ownership.xml · nonDerivative · entry 4

Rodino-Klapac Louise · CIK 0001836218 · Head of R&D, CSO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 84,631

F4 · price: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. 25% of the shares of common stock underlying each RSU will vest on the first anniversary of the grant date, and additional 25% will vest on each anniversary of the Grant Date thereafter, such that the RSUs will be fully vested on the fourth anniversary of the grant date.

Read SEC document
March 10, 2025 Filed Mar 12, 2025 00:00 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 Tax withholdingCommon Stock 2,539 $100.13 $254,230.07
Disclosure

SEC source: 0000950170-25-037523 · ownership.xml · nonDerivative · entry 3

Rodino-Klapac Louise · CIK 0001836218 · Head of R&D, CSO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 76,355

F3 · shares: Shares were sold by the Company to satisfy tax withholding obligations related to vesting of PSUs granted on March 7, 2022.

Read SEC document
March 10, 2025 Filed Mar 12, 2025 00:00 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 Tax withholdingCommon Stock 924 $100.13 $92,520.12
Disclosure

SEC source: 0000950170-25-037523 · ownership.xml · nonDerivative · entry 2

Rodino-Klapac Louise · CIK 0001836218 · Head of R&D, CSO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 78,894

F2 · shares: Shares were sold by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 7, 2022.

Read SEC document
March 07, 2025 Filed Mar 11, 2025 00:00 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 Tax withholdingCommon Stock 7,990 $103.70 $828,563.00
Disclosure

SEC source: 0000950170-25-036694 · ownership.xml · nonDerivative · entry 3

Rodino-Klapac Louise · CIK 0001836218 · Head of R&D, CSO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 74,318

F3 · shares: Shares were sold by the Company to satisfy tax withholding obligations related to vesting of PSUs granted on March 6, 2023.

Read SEC document
March 07, 2025 Filed Mar 11, 2025 00:00 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 Tax withholdingCommon Stock 514 $103.70 $53,301.80
Disclosure

SEC source: 0000950170-25-036694 · ownership.xml · nonDerivative · entry 2

Rodino-Klapac Louise · CIK 0001836218 · Head of R&D, CSO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 82,308

F2 · shares: Shares were sold by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 6, 2023.

Read SEC document
March 07, 2025 Filed Mar 12, 2025 00:00 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 Exercise / conversionPerformance Stock Units · Derivative 5,500 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-037523 · ownership.xml · derivative · entry 5

Rodino-Klapac Louise · CIK 0001836218 · Head of R&D, CSO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,500 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Represents the number of shares vested under a performance stock unit ("PSU") award granted to the Reporting Person on March 7, 2022. The number of shares earned was based on the Compensation Committee's determination of the Company's achievement of the milestones under the terms of the PSU.

F1 · derivative.exercise_date: Represents the number of shares vested under a performance stock unit ("PSU") award granted to the Reporting Person on March 7, 2022. The number of shares earned was based on the Compensation Committee's determination of the Company's achievement of the milestones under the terms of the PSU.

F1 · derivative.expiration_date: Represents the number of shares vested under a performance stock unit ("PSU") award granted to the Reporting Person on March 7, 2022. The number of shares earned was based on the Compensation Committee's determination of the Company's achievement of the milestones under the terms of the PSU.

Read SEC document
March 07, 2025 Filed Mar 12, 2025 00:00 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 Exercise / conversionCommon Stock 5,500 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-25-037523 · ownership.xml · nonDerivative · entry 1

Rodino-Klapac Louise · CIK 0001836218 · Head of R&D, CSO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 79,818

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Represents the number of shares vested under a performance stock unit ("PSU") award granted to the Reporting Person on March 7, 2022. The number of shares earned was based on the Compensation Committee's determination of the Company's achievement of the milestones under the terms of the PSU.

Read SEC document
March 06, 2025 Filed Mar 11, 2025 00:00 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 Exercise / conversionPerformance Stock Units · Derivative 17,500 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-036694 · ownership.xml · derivative · entry 4

Rodino-Klapac Louise · CIK 0001836218 · Head of R&D, CSO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 17,500 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Represents the number of shares vested under a performance stock unit ("PSU") award granted to the Reporting Person on March 6, 2023. The number of shares earned was based on the Compensation Committee's determination of the Company's achievement of the milestones under the terms of the PSU.

F1 · derivative.exercise_date: Represents the number of shares vested under a performance stock unit ("PSU") award granted to the Reporting Person on March 6, 2023. The number of shares earned was based on the Compensation Committee's determination of the Company's achievement of the milestones under the terms of the PSU.

F1 · derivative.expiration_date: Represents the number of shares vested under a performance stock unit ("PSU") award granted to the Reporting Person on March 6, 2023. The number of shares earned was based on the Compensation Committee's determination of the Company's achievement of the milestones under the terms of the PSU.

Read SEC document
March 06, 2025 Filed Mar 11, 2025 00:00 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 Exercise / conversionCommon Stock 17,500 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-25-036694 · ownership.xml · nonDerivative · entry 1

Rodino-Klapac Louise · CIK 0001836218 · Head of R&D, CSO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 82,822

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Represents the number of shares vested under a performance stock unit ("PSU") award granted to the Reporting Person on March 6, 2023. The number of shares earned was based on the Compensation Committee's determination of the Company's achievement of the milestones under the terms of the PSU.

Read SEC document
March 04, 2025 Filed Mar 7, 2025 01:00 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 Tax withholdingCommon Stock 1,704 $101.34 $172,683.36
Disclosure

SEC source: 0000950170-25-035002 · ownership.xml · nonDerivative · entry 1

Rodino-Klapac Louise · CIK 0001836218 · Head of R&D, CSO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,322

F1 · shares: Shares were sold by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 3, 2021.

Read SEC document
March 03, 2025 Filed Mar 5, 2025 01:00 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 Tax withholdingCommon Stock 715 $103.77 $74,195.55
Disclosure

SEC source: 0000950170-25-032759 · ownership.xml · nonDerivative · entry 1

Rodino-Klapac Louise · CIK 0001836218 · Head of R&D, CSO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 67,026

F1 · shares: Shares were sold by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 1, 2024.

F2 · balance_after: Amount of Securities Beneficially Owned includes 111 shares purchased under the Company's registered Employee Stock Purchase Plan on February 28, 2025.

Read SEC document
February 11, 2025 Filed Feb 14, 2025 01:00 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 GrantPerformance Restricted Stock Units · Derivative 3,500 $0.00 $0.00
Disclosure

SEC source: 0000950170-25-020193 · ownership.xml · derivative · entry 1

Rodino-Klapac Louise · CIK 0001836218 · Head of R&D, CSO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,500

Underlying: Common Stock · 3,500 shares

Expires not disclosed

F1 · derivative.exercise_price: Represents the total number of shares earned under a PSU award granted to the Reporting Person on March 6, 2023. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of the prescribed milestones under the terms of the PSU award. The earned PSUs will vest on March 6, 2025, subject to the Reporting Person continuing to provide service to the Company through such vesting date.

F1 · derivative.exercise_date: Represents the total number of shares earned under a PSU award granted to the Reporting Person on March 6, 2023. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of the prescribed milestones under the terms of the PSU award. The earned PSUs will vest on March 6, 2025, subject to the Reporting Person continuing to provide service to the Company through such vesting date.

F1 · derivative.expiration_date: Represents the total number of shares earned under a PSU award granted to the Reporting Person on March 6, 2023. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of the prescribed milestones under the terms of the PSU award. The earned PSUs will vest on March 6, 2025, subject to the Reporting Person continuing to provide service to the Company through such vesting date.

Read SEC document
November 18, 2024 Filed Nov 21, 2024 01:00 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 Tax withholdingCommon Stock 4,558 $102.89 $468,972.62
Disclosure

SEC source: 0000950170-24-129454 · ownership.xml · nonDerivative · entry 1

Rodino-Klapac Louise · CIK 0001836218 · Head of R&D, CSO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 67,630

F1 · shares: Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on November 16, 2021.

F2 · balance_after: Amount of Securities Beneficially Owned includes 47 shares purchased under the Company's registered Employee Stock Purchase Plan on August 30, 2024.

Read SEC document
June 24, 2024 Filed Jun 26, 2024 00:00 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 Tax withholdingCommon Stock 2,182 $164.64 $359,244.48
Disclosure

SEC source: 0000950170-24-077521 · ownership.xml · nonDerivative · entry 2

Rodino-Klapac Louise · CIK 0001836218 · Head of R&D, CSO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 72,141

F2 · shares: Shares were sold by the Company to satisfy tax withholding obligations related to vesting of PSUs granted on March 1, 2024.

Read SEC document
June 21, 2024 Filed Jun 26, 2024 00:00 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 Exercise / conversionPerformance Stock Units · Derivative 6,250 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-077521 · ownership.xml · derivative · entry 5

Rodino-Klapac Louise · CIK 0001836218 · Head of R&D, CSO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,250 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Represents the number of shares earned and vested under a performance stock unit ("PSU") award granted to the Reporting Person on March 1, 2024. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU. The PSUs vested immediately upon the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU.

F1 · derivative.exercise_date: Represents the number of shares earned and vested under a performance stock unit ("PSU") award granted to the Reporting Person on March 1, 2024. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU. The PSUs vested immediately upon the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU.

F1 · derivative.expiration_date: Represents the number of shares earned and vested under a performance stock unit ("PSU") award granted to the Reporting Person on March 1, 2024. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU. The PSUs vested immediately upon the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU.

Read SEC document
June 21, 2024 Filed Jun 26, 2024 00:00 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 GrantPerformance Stock Units · Derivative 6,250 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-077521 · ownership.xml · derivative · entry 4

Rodino-Klapac Louise · CIK 0001836218 · Head of R&D, CSO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,250

Underlying: Common Stock · 6,250 shares

Expires not disclosed

F1 · derivative.exercise_price: Represents the number of shares earned and vested under a performance stock unit ("PSU") award granted to the Reporting Person on March 1, 2024. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU. The PSUs vested immediately upon the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU.

F1 · derivative.exercise_date: Represents the number of shares earned and vested under a performance stock unit ("PSU") award granted to the Reporting Person on March 1, 2024. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU. The PSUs vested immediately upon the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU.

F1 · derivative.expiration_date: Represents the number of shares earned and vested under a performance stock unit ("PSU") award granted to the Reporting Person on March 1, 2024. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU. The PSUs vested immediately upon the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU.

Read SEC document
June 21, 2024 Filed Jun 26, 2024 00:00 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 GrantPerformance Stock Units · Derivative 5,500 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-077521 · ownership.xml · derivative · entry 3

Rodino-Klapac Louise · CIK 0001836218 · Head of R&D, CSO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,500

Underlying: Common Stock · 5,500 shares

Expires not disclosed

F3 · derivative.exercise_price: Represents the number of shares earned under a PSU award granted to the Reporting Person on March 7, 2022. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of prescribed milestones under the terms of the PSU award. The earned PSUs will vest on March 7, 2025, subject to the Reporting Person continuing to provide service to the Company through such vesting date.

F3 · derivative.exercise_date: Represents the number of shares earned under a PSU award granted to the Reporting Person on March 7, 2022. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of prescribed milestones under the terms of the PSU award. The earned PSUs will vest on March 7, 2025, subject to the Reporting Person continuing to provide service to the Company through such vesting date.

F3 · derivative.expiration_date: Represents the number of shares earned under a PSU award granted to the Reporting Person on March 7, 2022. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of prescribed milestones under the terms of the PSU award. The earned PSUs will vest on March 7, 2025, subject to the Reporting Person continuing to provide service to the Company through such vesting date.

Read SEC document
June 21, 2024 Filed Jun 26, 2024 00:00 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 Exercise / conversionCommon Stock 6,250 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-077521 · ownership.xml · nonDerivative · entry 1

Rodino-Klapac Louise · CIK 0001836218 · Head of R&D, CSO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 74,323

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Represents the number of shares earned and vested under a performance stock unit ("PSU") award granted to the Reporting Person on March 1, 2024. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU. The PSUs vested immediately upon the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU.

Read SEC document
March 08, 2024 Filed Mar 12, 2024 00:00 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 Tax withholdingCommon Stock 909 $123.14 $111,934.26
Disclosure

SEC source: 0000950170-24-029532 · ownership.xml · nonDerivative · entry 2

Rodino-Klapac Louise · CIK 0001836218 · Head of R&D, CSO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 68,073

F2 · shares: Shares were sold by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 7, 2022.

Read SEC document
March 07, 2024 Filed Mar 12, 2024 00:00 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 Tax withholdingCommon Stock 512 $120.49 $61,690.88
Disclosure

SEC source: 0000950170-24-029532 · ownership.xml · nonDerivative · entry 1

Rodino-Klapac Louise · CIK 0001836218 · Head of R&D, CSO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 68,982

F1 · shares: Shares were sold by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 6, 2023.

Read SEC document
March 04, 2024 Filed Mar 7, 2024 01:00 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 Tax withholdingCommon Stock 1,728 $125.32 $216,552.96
Disclosure

SEC source: 0000950170-24-027496 · ownership.xml · nonDerivative · entry 1

Rodino-Klapac Louise · CIK 0001836218 · Head of R&D, CSO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 69,494

F1 · shares: Shares were sold by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 3, 2021.

Read SEC document
March 01, 2024 Filed Mar 6, 2024 01:00 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 GrantStock Option (right to buy) · Derivative 12,500 $0.00 Strike: $128.67 $0.00
Disclosure

SEC source: 0000950170-24-026607 · ownership.xml · derivative · entry 3

Rodino-Klapac Louise · CIK 0001836218 · Head of R&D, CSO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,500

Underlying: Common Stock · 12,500 shares

Expires 2034-03-01

F4 · derivative.exercise_date: Represents the date upon which the first 25% of the option granted vests. 1/48th of the total granted option vests and become exercisable on each monthly anniversary thereafter.

Read SEC document
March 01, 2024 Filed Mar 6, 2024 01:00 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 GrantCommon Stock 6,000 $0.00 $0.00
Disclosure

SEC source: 0000950170-24-026607 · ownership.xml · nonDerivative · entry 2

Rodino-Klapac Louise · CIK 0001836218 · Head of R&D, CSO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 71,222

F3 · price: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. 25% of the shares of common stock underlying each RSU will vest on the first anniversary of the grant date, and additional 25% will vest on each anniversary of the Grant Date thereafter, such that the RSUs will be fully vested on the fourth anniversary of the grant date.

Read SEC document
March 01, 2024 Filed Mar 6, 2024 01:00 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 Tax withholdingCommon Stock 778 $126.19 $98,175.82
Disclosure

SEC source: 0000950170-24-026607 · ownership.xml · nonDerivative · entry 1

Rodino-Klapac Louise · CIK 0001836218 · Head of R&D, CSO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,222

F1 · shares: Shares were sold by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on February 28, 2020.

F2 · balance_after: Amount of Securities Beneficially Owned includes 249 shares purchased under the Company's registered Employee Stock Purchase Plan on February 29, 2024.

Read SEC document
November 17, 2023 Filed Nov 21, 2023 01:00 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 Tax withholdingCommon Stock 4,508 $82.98 $374,073.84
Disclosure

SEC source: 0001209191-23-056168 · doc4.xml · nonDerivative · entry 1

Rodino-Klapac Louise · CIK 0001836218 · Head of R&D, CSO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,751

F1 · shares: Shares were sold by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on November 16, 2021.

F2 · balance_after: Amount of Securities Beneficially Owned includes 89 shares purchased under the Company's registered Employee Stock Purchase Plan on August 31, 2023.

Read SEC document
March 08, 2023 Filed Mar 11, 2023 01:00 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 Tax withholdingCommon Stock 912 $153.19 $139,709.28
Disclosure

SEC source: 0001209191-23-018021 · doc4.xml · nonDerivative · entry 1

Rodino-Klapac Louise · CIK 0001836218 · Head of R&D, CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,170

F1 · shares: Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 7, 2022.

Read SEC document
March 06, 2023 Filed Mar 9, 2023 01:00 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 GrantStock Option (right to buy) · Derivative 27,000 $0.00 Strike: $155.99 $0.00
Disclosure

SEC source: 0001209191-23-017407 · doc4.xml · derivative · entry 3

Rodino-Klapac Louise · CIK 0001836218 · Head of R&D, CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,000

Underlying: Common Stock · 27,000 shares

Expires 2033-03-06

F3 · derivative.exercise_date: Represents the date upon which the first 25% of the option granted vests. 1/48th of the total granted option vests and become exercisable on each monthly anniversary thereafter.

Read SEC document
March 06, 2023 Filed Mar 9, 2023 01:00 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 GrantCommon Stock 4,500 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-017407 · doc4.xml · nonDerivative · entry 2

Rodino-Klapac Louise · CIK 0001836218 · Head of R&D, CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 71,082

F2 · price: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. 25% of the shares of common stock underlying each RSU will vest on the first anniversary of the grant date, and additional 25% will vest on each anniversary of the Grant Date thereafter, such that the RSUs will be fully vested on the fourth anniversary of the grant date.

Read SEC document
March 06, 2023 Filed Mar 9, 2023 01:00 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 Tax withholdingCommon Stock 1,134 $157.21 $178,276.14
Disclosure

SEC source: 0001209191-23-017407 · doc4.xml · nonDerivative · entry 1

Rodino-Klapac Louise · CIK 0001836218 · Head of R&D, CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 66,582

F1 · shares: Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 3, 2021.

Read SEC document
March 01, 2023 Filed Mar 4, 2023 01:00 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 Tax withholdingCommon Stock 522 $147.57 $77,031.54
Disclosure

SEC source: 0001209191-23-016054 · doc4.xml · nonDerivative · entry 1

Rodino-Klapac Louise · CIK 0001836218 · Head of R&D, CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,716

F1 · shares: Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on February 28, 2020.

F2 · balance_after: Amount of Securities Beneficially Owned includes 240 shares purchased under the Company's registered Employee Stock Purchase Plan on February 28, 2023.

Read SEC document
November 17, 2022 Filed Nov 22, 2022 01:02 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 Tax withholdingCommon Stock 4,211 $108.52 $456,977.72
Disclosure

SEC source: 0001209191-22-058284 · doc4.xml · nonDerivative · entry 1

Rodino-Klapac Louise · CIK 0001836218 · Head of R&D, CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,998

F1 · shares: Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on November 16, 2021.

F2 · balance_after: Amount of Securities Beneficially Owned includes 98 shares purchased under the Company's registered Employee Stock Purchase Plan on August 31, 2022.

Read SEC document
March 07, 2022 Filed Mar 9, 2022 01:00 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 GrantStock Option (right to buy) · Derivative 48,000 $0.00 Strike: $80.42 $0.00
Disclosure

SEC source: 0001209191-22-017343 · doc4.xml · derivative · entry 3

Rodino-Klapac Louise · CIK 0001836218 · Head of R&D, CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,000

Underlying: Common Stock · 48,000 shares

Expires 2032-03-07

F3 · derivative.exercise_date: Represents the date upon which the first 25% of the option granted vests. 1/48th of the total granted option vests and become exercisable on each monthly anniversary thereafter.

Read SEC document
March 07, 2022 Filed Mar 9, 2022 01:00 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 GrantCommon Stock 8,000 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-017343 · doc4.xml · nonDerivative · entry 2

Rodino-Klapac Louise · CIK 0001836218 · Head of R&D, CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 72,111

F2 · price: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. 25% of the shares of common stock underlying each RSU will vest on the first anniversary of the grant date, and additional 25% will vest on each anniversary of the Grant Date thereafter, such that the RSUs will be fully vested on the fourth anniversary of the grant date.

Read SEC document
March 04, 2022 Filed Mar 9, 2022 01:00 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 Tax withholdingCommon Stock 1,216 $79.20 $96,307.20
Disclosure

SEC source: 0001209191-22-017343 · doc4.xml · nonDerivative · entry 1

Rodino-Klapac Louise · CIK 0001836218 · Head of R&D, CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 64,111

F1 · shares: Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 3, 2021.

Read SEC document
March 01, 2022 Filed Mar 2, 2022 01:03 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 Tax withholdingCommon Stock 572 $75.05 $42,928.60
Disclosure

SEC source: 0001209191-22-014409 · doc4.xml · nonDerivative · entry 1

Rodino-Klapac Louise · CIK 0001836218 · Head of R&D, CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,327

F1 · shares: Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on February 28, 2020.

F2 · balance_after: The amount of securities directly owned by the reporting person includes 221 shares of common stock purchased under the Company's Amended and Restated 2013 Employee Stock Purchase Plan on February 28, 2022.

Read SEC document
November 24, 2021 Filed Nov 29, 2021 13:00 UTC Sarepta Therapeutics, Inc. SRPT · Entity 4426 PurchaseCommon Stock 3,780 $79.33 $299,867.40
Disclosure

SEC source: 0001209191-21-066948 · doc4.xml · nonDerivative · entry 1

Rodino-Klapac Louise · CIK 0001836218 · Head of R&D, CSO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,678

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.